NCT00496431 2022-01-27phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma PatientsItalfarmacoPhase 1/2 Terminated19 enrolled
NCT00792467 2021-05-11Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's LymphomaItalfarmacoPhase 1/2 Completed24 enrolled 13 charts